Monash IVF 2026Q4业绩及2030战略规划电话会议纪要

发布时间：2026-08-31 一、AI总结内容 一、核心要点 1. FY26营收2.69亿澳元，EBITDA5340万澳元，净利润1610万澳元，低于指引，含140万澳元预付资产核销；下半年国内IVF刺激周期同比提升10个百分点，市场份额增长120基点至20.2%。 2. 发布新战略Nurture 2030，核心为以患者为中心，向整合型生殖健康服务转型，同步推进临床、科技、人才建设。 3. 亚洲业务FY26创纪录， volume和利润双增，新柔地铁2027年1月通车将促进区域互联。 二、运营与财务细节 1. FY26下半年国内IVF刺激周期改善，冷冻胚胎移植稳定，生殖诊断如PGT、胚胎筛查增长显著；诊断收入增长， day surgery收入受开业初期影响略有下降但 volume微增。 2. 医疗团队扩充，FY26新增13名专科医生，完善生育服务能力，关闭老克莱顿设施，新克莱顿诊所即将开业，升级患者体验。 3. FY26资本开支周期收尾，FY27资本开支预计减幅超50%，重点转向资产利用率优化，折旧摊销及利息支出预计大体稳定，运营现金流同比提升，现金转化率85%，净债务上升，杠杆率和利息覆盖仍有缓冲。 4. 全球不孕症发病率未来10年或增50%，澳大利亚刺激周期潜在增幅超30%，亚洲地区增幅50%-60%，长期需求增长明确。 三、风险与关注 1. 国内IVF市场上半年承压，新南威尔士州市场份额待巩固，运营效率提升进度需跟进。2. 行业将从自我监管转向全国标准监管，需应对合规投入，医疗人才竞争激烈。四、后续计划 1. FY27目标：有机 volume增长、市场份额提升、EBITDAmargin改善及现金转化；深化Nurture 2030战略，推进精准医疗、数字化转型和科研合作。2. FY27上半年将披露更清晰的国内市场增长指引，聚焦核心区域市场拓展及效率提升。 二、音频原文（转写） important The FY '26 result reflects a year in which the first half absorbed a number of significant pressures reactive domestic volume and market share pressures, macroeconomic uncertainty, deferred pricing across the Eastern Coast and a cost base that had not adjusted quickly enough tothe changing environment. Those pressures flowed through to the full year result and importantly, the full year numbers masked the very differe nt trajectory we saw in the second half, fueledby a coordinated plan to address and restore underlying performance. noting the pleasing resilience of top line revenue. That work has only justbegun, but it is encouraging to see the business already beginning to respond. We saw domesticvolumes in IVF improve 10 percentage points in the second 6 months, with total group FY 26 stimulated cycles of 11,423. Australian domestic market share grew 120 basis points on a 6-month rolling average comparison. to twenty point two percent We had significantly stronger doctor recruitment progress on productivity and greater utilization of the enhanced asset capacity. So while t he FY '26 financial result reflect the entiretyof what can only be described as an atypical year The underlying direction of the business changed materially. as the year progressed and the second half performance gives us a much clearer view of where the business is heading. Over the last month. We have begun to change the underlyingeconomics of the business. FY 26 exposed wherethe model was carrying too much friction. pressure on volume, pricing restraint and a cost basethat wasn't sufficiently agile. We have spent the second half beginning to address those structural issues rather than sim treating the symptoms. We are creating the conditions for growth andproductivity to reinforce each other. The investment cycle has created capacity The strength inmedical workforce is beginning to unlock greaterutilization across the network. We have returned to our normal pricing cadence. And the productivity program is now underway across the areas where we see the greatest opportunity to improveefficiency. Alongside that, diagnostics and thebroader reproductive health opportunity are begi nning to open clear avenues for revenue and volu me growth alongside the traditional IVF cycle. F Y 27 is about taking early traction to sustainedoperating and financial performance with execut ion that must remain operationally dynamic. Domestic IVF was the area Greatest pressure in the early part of FY twenty six with stimulated treatment cycles easing predominantly in the first half. Frozen embryo transfer activity was more resilient with a slight decline following an unusually strong FY twenty five. But we also began tosee early but tangible benefits of operational efficiency changes with a modest one point sevenpercent reduction in variable IVF costs. While still early, the initial benefit marks the beginning of a broader shift towards a more efficientand productive cost base in our larger. businessunit. The national market share position reflects a range of underlying trends across our statemarkets. We have maintained our dominant position in South Australia. have outperformed in market share growth in Western Australia and are seeing solid growth in Queensland. Victoria is showing improvement, while New South Wales remainedan opportunity from a smaller base. And we are well under way with targeted strategies to strengthen our position in both of these states. Morefundamentally, we have reshaped the medical platform We have increased the number of fertility specialists and trainees, while also materially improving the depth and mix of our fertility capabilities. with a stronger skills matrix, largerpractices and greater capacity in the markets where we see the greatest opportunity This is notsimply about adding numbers. It is about building the right clinical capability, aligned medicalleadership and practice. scale for the future.in the markets that matter most. underpinning this, the infrastructure investment we have already made The closure of our original 1980s Claytonfacility marks the end of an important chapterin Monash IVS histor